FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.
Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.
Larry Norton wins ASCO’s Karnofsky award.
Funding opportunities listed.
May issue of Business & Regulatory Report, 8 additional pages, included.
Trending Stories
- Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures - Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- Rathmell announces new cancer screening network, new NCI virtual clinical trials office
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities